Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma

Cancer

Volumn 115, Issue 21, 2009, Pages 5117-5125

  McIntosh, Alyson ^a   Hagspiel, Klaus D ^a   Al Osaimi, Abdullah M ^a   Northup, Patrick ^a   Caldwell, Stephen ^a   Berg, Carl ^a   Angle, J Fritz ^a   Argo, Curtis ^a   Weiss, Geoffrey ^a   Rich, Tyvin A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Accelerated radiotherapy; Capecitabine; Hepatocellular carcinoma; Intensity modulated radiotherapy; Tomotherapy

Indexed keywords

CAPECITABINE; DOXORUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; LACTULOSE; MITOMYCIN C; PARACETAMOL; PROTON PUMP INHIBITOR; STEROID;

ACCELERATION; ACUTE HEPATITIS; ACUTE TOXICITY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BRAIN DISEASE; CANCER CONTROL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EVALUATION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; ESOPHAGUS VARICES; EVENING DOSAGE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MORNING DOSAGE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; SEPSIS; STOMACH ULCER; TOMOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 70350519944     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24552     Document Type: Article

References (25)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340: 745-750. (Pubitemid 29114292)
2. Krishnan S, Dawson LA, Seong J, et al. Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol. 2008;15:1015-1024.
3. Cheng S, Lin Y, Chuang V, et al. A pilot study of 3-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14:1025-1033. (Pubitemid 29487300)
4. Mornex F, Girard N, Beziat C, et al. Feasibility and efficacy of high-dose 3-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 2006;66:1152-1158. (Pubitemid 44740208)
5. Robertson JM, Lawrence TS, Dworzanin LM, et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol. 1993; 11:1286-1293. (Pubitemid 23199131)
6. Zhou ZH, Liu LM, Chen WW, et al. Combined therapy of transcatheter arterial chemoembolisation and 3-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol. 2007;80:194-201. (Pubitemid 47007810)
7. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26:657-664. (Pubitemid 351264363)
8. Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:150-155. (Pubitemid 34899660)
9. Solomon B, Soulen MC, Baum RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-c, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. J Vasc Interv Radiol. 1999;10:793-798. (Pubitemid 29284310)
10. Seong J, Keum KC, Han KH, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:393-397. (Pubitemid 29091482)
11. Seong J, Park HC, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys. 2000;47:1331-1335. (Pubitemid 30421186)
12. Jeraj R, Mackie TR, Balog J, et al. Radiation characteristics of helical tomotherapy. Med Phys. 2004;31:396-404.
13. Mackie TR, Balog J, Ruchala K, et al. Tomotherapy. Semin Radiat Oncol. 1999;9:108-117.
14. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948-2953. (Pubitemid 29493974)
15. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004;22:2214-2232.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
17. Gierga DP, Chen GTY, Kung JH, et al. Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. Int J Radiat Oncol Biol Phys. 2004;58:1584-1595.
18. Kanagaki B, Read PW, Molloy JA, et al. A motion phantom study on helical tomotherapy: the dosimetric impacts of delivery technique and motion. Phys Med Biol. 2007;52: 243-255. (Pubitemid 46646277)
19. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210-2218. (Pubitemid 30350212)
20. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-8747. (Pubitemid 46211519)
21. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739. (Pubitemid 34607087)
22. Lo C-M, Ngan H, Wai-Kuen T, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35: 1164-1171. (Pubitemid 34454013)
23. Zeng Z, Tang Z, Jia F, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 2004;10: 307-316. (Pubitemid 44403469)
24. Liang S-X, Jiang GL, Zhu X-D, et al. Hypofractionated 3- dimensional conformal radiation therapy for primary liver carcinoma. Cancer. 2005;103:2181-2188. (Pubitemid 40605127)
25. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.